NewsBenzinga암젠, 쇼그렌병 치료제 다조달리벱의 3상 임상시험(OASIZ 301)에서 1차 평가 지표 충족 및 48주차 전신 질환 활성도 개선 발표 암젠, 쇼그렌병 치료제 다조달리벱의 3상 임상시험(OASIZ 301)에서 1차 평가 지표 충족 및 48주차 전신 질환 활성도 개선 발표 Benzinga 2026.09.22 13:02 (GMT+0) Open on Benzinga Other news Puma Biotechnology Reports Q2 2026 Results: Full Earnings Call Transcript Transcript: Rocket Companies Q2 2026 Earnings Conference Call Reported Earlier, China Passenger Car Sales Fall 28.1% YoY To 1.63M In September, Tesla Exported 30,529 China-Made Vehicles, Per CPCA SWI Group completes €800 million financing to accelerate conversion of Bitcoin mining sites into AI computing infrastructure Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…' Full Transcript: MDU Resources Gr Q2 2026 Earnings Call
Reported Earlier, China Passenger Car Sales Fall 28.1% YoY To 1.63M In September, Tesla Exported 30,529 China-Made Vehicles, Per CPCA
SWI Group completes €800 million financing to accelerate conversion of Bitcoin mining sites into AI computing infrastructure
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
